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4.
in the PICOS description, please make sure what are the outcomes. 5.
the statistical method page 6 line 6-7 should move to or merge into Data analysis, rather than repeating them in different sections. 6.
What is meaning of "because we assume each trial varies markedly " in Page 7 line 30. Are we going to include trials in this study?
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GENERAL COMMENTS
I recommend having the manuscript be reviewed and edited for grammatical purposes.
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GENERAL COMMENTS
This a well-documented study protocol for a systematic review and meta-analysis on prevalence and risk factors of depression after lung cancer. The protocol is detailed and seems methodologically sound. It makes use of available checklists and deals with a topic that may be highly relevant for lung cancer patients. However, I have a few comments that may strengthen the paper. The paper may benefit from a careful checking of grammar and format, sometimes words are missing in sentences, spaces are at the wrong place. Abstract • My recommendation is to shorten the part on analysis. It is too detailed. Strenghts and Limitations:
• What do you mean with the last point? It seems you are not including cross-sectional studies but then excuse for including them… • A strenght in my opinion is the stnadardized methodology, standardized study rating and use of checklists (guidelines of reviews).
• I think this part should be formulated in bullet points, max one sentence. Please check if your format complies with the journal style. Introduction:
• In ethics and dissemination the practical usefulness of this review is described. I am missing a part on what can be done with these results in the introduction.
• A paragraph (p. 3, line 3-12) is written as if risk factors for depression among lung cancer patients are already established. I guess, this is not the case and would make parts of this paper unnecessary. I suggest to cite a couple of relevant studies and point to similarities/differences and to highlight the need to systematically assess groups at risk. This is what the authors are doing in the last paragraph (p. 3, line 33-47) . I suggest to restructure here.
• The reasons for conducting this meta-analysis should be strenghtened. In my opinion, robust evidence for risk factors are an advantage because of their predicitve power. One might also think that certain risk facors may be attenuated or decreased during disease/treatment or that interventions aim at these specific risk factors and decrease their impact on depression..
• Objective: Is the authors' aim to evalaute the existing research? I believe "assess" is the more appropriate term. • Search Strategy: Does it make sense to group depression etc. under intervention and risk factors under outcome? I believe it makes more sense the other way around: depression is the outcome.
• Data Extraction: how are "cases of depression" identified? Scales in different papers often report different cut-offs, this should be taken into account. Furthermore, will only studies be included that report prevalences? What about symptom scores (means)? Risk factors are still missing. Maybe it makes sense to include a statement that the variables extracted will be adjusted in the process as likely more and more variables will turn up that need to be included in your list.
• Data Analysis: Please specify the conditions under which "a meta-analysis is possible • Please make some more suggestions regarding subgroups. Furthermore, I think some groups should be defined before -why do you want to wait until extraction? I suggest to include subgroups on bias score, time since diagnosis (long-vs short-term survivors), severity/staging of lung cancer, study design. Please leave your comments for the authors below The authors try to estimate the prevalence of depression and its associated risk factor among lung cancer patients. overall, this article is well written. However, there are still some unclear points to be addressed. 1. The cross-sectional studies were excluded from this review, which will consequently miss out some studies with prevalence. this will bias the estimates of prevalence in this study. R: We will exclude cross-sectional studies for its poor evidence on identifying causal relationship. This will bias the estimates of prevalence, which is one limitation in this study. 2. There are several questionnaires assessing the status of depression. the prevalence of depress will under/overestimate by the questionnaires themselves. Please clarify how to standardize and merge the rate across different scales. R: In the Data analysis part, we added "Prevalence estimates reported by the individual studies will be extracted or converted into percent prevalence and their respective standard errors will be calculated. For the depression scores, SMD will be used for analysis." 3. the risk factors could be reported in different ways in different studies. some studies could only report the significant factors, but others may only report the factors of interest. Please clarify a) what are the expected risk factors; b) how to combine/present this information. R: In the data extraction part, we added " Possible risk factors include but are not limited to gender, age, occupation, marital status, education level, social support, alcohol status, smoking status, pathological type, cancer clinical stage, KPS, disease course and therapy method. The variables extracted will be adjusted in the process as likely more and more variables will turn up that need to be included." 4. in the PICOS description, please make sure what are the outcomes. R: Depression should be the outcome. So, in the PICOS description, we changed the outcome to "(depression/ depressive symptom/ depressive disorder/ depressed)" 5. the statistical method page 6 line 6-7 should move to or merge into Data analysis, rather than repeating them in different sections. R: we have already moved them to Data analysis part. 6. What is meaning of "because we assume each trial varies markedly " in Page 7 line 30. Are we going to include trials in this study? R: No, we will include clinical studies. In the data analysis part, we changed trial to study. _____________________________________________________________________________ Reviewer: 3 Reviewer Name: Bonnie Leung Institution and Country: BC Cancer, Canada Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below I recommend having the manuscript be reviewed and edited for grammatical purposes. R: we have already tried our best to modify the gramma. Please leave your comments for the authors below This a well-documented study protocol for a systematic review and meta-analysis on prevalence and risk factors of depression after lung cancer. The protocol is detailed and seems methodologically sound. It makes use of available checklists and deals with a topic that may be highly relevant for lung cancer patients. However, I have a few comments that may strengthen the paper.
The paper may benefit from a careful checking of grammar and format, sometimes words are missing in sentences, spaces are at the wrong place.
Abstract
• My recommendation is to shorten the part on analysis. It is too detailed. R: We have already shortened this part. Strenghts and Limitations:
• What do you mean with the last point? It seems you are not including cross-sectional studies but then excuse for including them… R: Right, we will not include cross-sectional studies. In this part, we changed it to" We will exclude cross-sectional studies for its poor evidence on identifying causal relationship in this study, which may bias the estimates of prevalence." • A strenght in my opinion is the stnadardized methodology, standardized study rating and use of checklists (guidelines of reviews). R: we have added using guidelines in this part.
• I think this part should be formulated in bullet points, max one sentence. Please check if your format complies with the journal style. R: We have already changed them to one sentence respectively.
Introduction:
• In ethics and dissemination the practical usefulness of this review is described. I am missing a part on what can be done with these results in the introduction. R: In the Introduction part, we added "The findings of this study would assist clinicians in identifying lung cancer patients with depression and provide the evidence for programming early targeted interventions to high-risk survivors" • A paragraph (p. 3, line 3-12) is written as if risk factors for depression among lung cancer patients are already established. I guess, this is not the case and would make parts of this paper unnecessary. I suggest to cite a couple of relevant studies and point to similarities/differences and to highlight the need to systematically assess groups at risk. This is what the authors are doing in the last paragraph (p. 3, line 33-47) . I suggest to re-structure here. R: In paragraph 3 of the introduction part, we added "some of the results are inconsistent. For example, Several studies suggest that female is an independent risk factor for depression in lung cancer patients,7 13 while others have found gender is not associated with depression9 14 Part of studies demonstrate that older14 /younger13 is an independent risk factor. However, some researchers present that age is not a predicting factor for depression.9 15 Therefore, we decided to conduct a systematic review and meta-analysis to provide robust evidence for risk factors related to depression." • The reasons for conducting this meta-analysis should be strenghtened. In my opinion, robust evidence for risk factors are an advantage because of their predicitve power. One might also think that certain risk facors may be attenuated or decreased during disease/treatment or that interventions aim at these specific risk factors and decrease their impact on depression.. R: We added" Therefore we decided to conduct a systematic review and meta-analysis to provide robust evidence for risk factors related to depression. The findings of this study would assist clinicians in identifying lung cancer patients with depression and provide the evidence for programming early targeted interventions to high-risk survivors, which can attenuate these negative emotional reactions." • Objective: Is the authors' aim to evalaute the existing research? I believe "assess" is the more appropriate term. R: We changed "evaluate" to "assess" in the Objective part.
• Method:
• Why do the authors only include research until November 2018? R: Because we need to design the publication date in the search strategy when registering PROSPERO, and November 2018 is the registration time. But the final publication date will limit between 1 January 1975 to the last search date.
• Do I understand correctly that you are intending to only include longitundinal studies (no crosssectional)? The exclusion criteria suggest this (while the inclusion criteria do not make this clear). If so, this should be stated as a strenghts and the rationale for this choice should be provided. The choice of study designs seems not coherent throughout the paper. R: Yes, we just include cohort and case-control studies. We added "We will only include cohort and case-control studies (with a sample of at least 30) because of their strong evidence on identifying significant risk factors." in inclusion criteria part. And we put this as a strength.
• "Type of Participants: lung cancer patients with depression"  I understand that you would like to assess prevalence and risk factors of depression, so I think that type of participants are rather lung cancer patients in general? R: Yes, we changed it to lung cancer patients.
• P.4, line 40: What does incomplete data mean? When is data considered incomplete? R: We added "For example, studies without complete baseline data, or without OR value, or OR value and 95% CI can not be calculated will not be included." • A word is missing: "Search methods for identification relevant studies" R: We added "of".
